Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?-Reference-Cited by-同舟云学术

Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?

Published:2010-07-12 Issue:12 Volume:12 Page:1023-1035
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:

Author:

Schernthaner G.,Chilton R. J.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2010.01262.x/fullpdf

Reference86 articles.

1. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).;Rydén;Eur Heart J,2007

2. Lessons from the glitazones: a story of drug development.;Gale;Lancet,2001

3. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.;Dormandy;Lancet,2005

4. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.;Lancet,2006

5. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.;Kahn;N Engl J Med,2006

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial;Frontiers in Endocrinology;2023-01-09

2. Evaluation of the anti-diabetic effect of biogenic silver nanoparticles and intervention in PPARγ gene regulation;Environmental Research;2022-12

3. New therapies for diabetes mellitus;Pathy's Principles and Practice of Geriatric Medicine;2022-02-18

4. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease;Advances in Therapy;2019-03-19

5. Evolution of Glucose-Lowering Drugs for Type 2 Diabetes;Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome;2018